FIRST AMENDMENT to AGREEMENT FOR ANTIBODY DISCOVERY AND DEVELOPMENTAgreement for Antibody Discovery and Development • March 30th, 2010 • Omeros Corp • Pharmaceutical preparations
This is a first amendment (this “Amendment”) effective as of March 26, 2010 to the Agreement for Antibody Discovery and Development dated July 25, 2008 related to antibodies to MASP-2 (the “Agreement”) between Omeros Corporation (“Omeros”), a Washington corporation having an address at 1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and Affitech AS (“Affitech”), having an address at Oslo Research Park, Gaustadalléen 21, N-0349 Oslo, Norway. Unless otherwise defined herein, all initially-capitalized terms used in this Amendment shall have the same definition as set forth in the Agreement.
